The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 38% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $164.
Ducommun Incorporated
DCO · the NYSE · USD · Market cap $2.5B · 2,130 employees
Ducommun Incorporated provides engineering and manufacturing services for products and applications used in the aerospace and defense, industrial, medical, and other industries in the United States.
FAIL · Does not pass the screenAt the last full screen
2026-09-07
Screened 2026-09-07 · the tape above runs as of 19:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its distribution label.
Ducommun Incorporated holds its Distribution at $168.32. Elevated stress, defensive posture warranted, held for 1 days.
| Phase | Distribution · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 1 days |
| Price at the screen | $168.32 |
| Valuation | N/A trailing · 31.39 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 1.04 |
Five Screens, Shown in Full
Does not pass. Prohibited business activity: Aerospace & Defense
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited business activity: Aerospace & Defense | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-09-07 screen. The gold marker is the market price at the same screen. The price runs 12.0% above the base estimate.
Third-party analyst targets: 5 covering, consensus None. The average target sits +24% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-07 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsDefense Contractor Trips Ethical Screen at High Price
Every time a fighter jet rolls off the line or a missile guidance system gets upgraded, Ducommun is somewhere in the supply chain turning raw metal and electronics into finished parts. The business sits squarely inside aerospace and defense, which immediately fails our ethical screen. We pass for that reason alone, before the numbers even enter the conversation.
Revenue is growing at 9 percent, yet profit margins sit at minus 3 percent and return on equity is minus 4 percent. The shares trade at 32.9 times forward earnings, well above our fair value of 124.41 against the current 168.47 price. Analyst targets sit higher still, but none of that offsets the prohibited activity that keeps the name off any list we would consider.
The ethical failure is permanent for us, regardless of margin of safety or cyclical recovery hopes. Negative returns and a stretched multiple only reinforce the decision to stay away. Analysis, not advice.
| Forward P/E | 31.4xexpensive even after accounting for its growth |
| EPS, trailing | -1.25 |
| EPS, forward | 5.36 |
| Revenue growth | +11.8%steady growth |
| Profit margin | -2.5%currently unprofitable |
| Return on equity | -3.0%not currently earning a positive return on equity |
| FCF yield | 2.26% |
| Debt to equity | 0.48minimal debt: a conservative balance sheet |
| Current ratio | 3.36comfortably covers its short-term bills |
| Beta | 1.04moves a little more than the market |
| Short interest, float | 0.05% |
| 52-week range | 84.76 - 210.39 |
| Market cap | $2.5B |
| Employees | 2,130 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeDCO trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 38% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $164.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 38% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 107%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it strong buy, with a mean price target of $164.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-08-26 | David Taylor | Republican | buy | 1K–15K |
| 2026-08-26 | David Taylor | Republican | buy | 1K–15K |
| 2026-08-26 | David Taylor | Republican | buy | 1K–15K |
| 2026-08-26 | David Taylor | Republican | buy | 1K–15K |
| 2026-08-26 | David Taylor | Republican | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $140.68 | +9.1% | · | $1,091 | +9.1% |
| 2 months | $139.99 | +9.6% | · | $1,096 | +9.6% |
| 3 months | $125.68 | +22.1% | · | $1,221 | +22.1% |
| 6 months | $95.11 | +61.3% | · | $1,613 | +61.3% |
| 1 year | $74.00 | +107.4% | · | $2,074 | +107.4% |
| 2 years | $58.00 | +164.6% | · | $2,646 | +164.6% |
| 3 years | $45.77 | +235.3% | · | $3,353 | +235.3% |
| 5 years | $56.35 | +172.3% | · | $2,723 | +172.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever DCO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.